Armata Pharmaceuticals, Inc. (ARMP): debt financing — Armata Pharma enters $10M secured credit agreement with Innoviva at 14% p.a., matures March 2026

Armata Pharmaceuticals, Inc.

$10 million term loan from Innoviva at 14.0% annual interest, secured by substantially all assets.
Loan matures March 12, 2026; proceeds to fund development of phage candidates AP-PA02 and AP-SA02.
Amendments extend maturity of three prior Innoviva credit agreements also to March 12, 2026.
Innoviva is Armata's largest shareholder; loan guaranteed by domestic subsidiaries.
Company pursuing additional non-dilutive funding for late-stage trials.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Armata Pharmaceuticals, Inc. incurred credit facility of $10 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing March 12, 2026.

Instrument: credit facility
Principal: $10 million
Counterparty: Innoviva Strategic Opportunities LLC
Rate: 14.0% per annum
Maturity: March 12, 2026
Event: incurrence

Exact text from the filing

The March 2025 Credit Agreement provides for a secured term loan facility in an aggregate amount of $10 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of March 12, 2026.

View on SEC.gov

73 debt financings filed in the last 30 days. Browse all debt financings →

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-023015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.